clinical trial · NCT05579899
Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
Atopic Dermatitis EczemaEVO101
brief summary
This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis
started
Sep 27, 2022
primary completion
Jul 27, 2023
completion
Jul 27, 2023
last updated
Mar 5, 2025
detailed description
This is a Phase 2a safety and efficacy study of EVO101 Topical Cream, 0.1%, applied twice daily for 8 weeks in adults with mild-to moderate atopic dermatitis.
official title
A Randomized, Vehicle-controlled, Safety and Efficacy Study of EVO101 in Adult Subjects With Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol